Journal of Parkinson s Disease · 2019 · 29 citations · 10 references
MedicineNeurologyPharmacologyClinical NeuroscienceClinical PharmacologyGene TherapyClinical Trial PhasesClinical TrialsEfficacy EvaluationNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersDisease-modifying GenesDisease-modifying Therapy DevelopmentDyskinesia ReductionParkinson Disease Gene TherapyParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentSymptom Relief Therapy
252 1. Change in "On time" without troublesome dyskinesia during waking hours. 2. Change in the number of total daily LD doses. 3. Clinical Global Impression Improvement (CGI-I), as recorded by physician & patient. 4. Change in total UPDRS Score (sum of Parts I-III).
10
A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease
Shin‐ichi Muramatsu, Kenichi Fujimoto, Seiya Kato et al. · Molecular Therapy · 2010 · 338 citations · Full text
Medicine, Neurology, Neuroscience +17
Alan Whone, Matthias Luz, M Boca et al. · Brain · 2019 · 283 citations · Full text